Bioventix(BVXP) Stock Analysis | Healthcare

GBX --+0.00%

Reward52Moderate

Risk21Low

75%Data

Strong 59% profit margin · 8.7% dividend yield · Revenue down 9% YoY

Defensive Anchor

Market Cap:89.08M

ⓘ

Reward Rating

Moderate

Reward Assessment

75% data coverage

Bottom 50% of stocksView factors

ⓘ

Risk Rating

Low

Risk Assessment

Risk factors availableUnlock details

Earnings & dividend markersEarnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bioventix?

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

AI Brief Pro

The brief on Bioventix

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Bioventix?

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 89.08M, and a P/E ratio of 12.2x.